Loading
NASDAQHealthcareBiotechnology
Latest quote
$487.72
−$8.73 · -1.76%
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Previous close
$487.72
−$8.73 · -1.76%
After-hours
$480
−$7.72 · -1.58%
Oct 7, 7:50 PM ET
Regular session · ET · Market data may be delayed.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Day range
Current $487.72
52-week range
Current $487.72
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
93
Deep Value
Sentiment
55
Mixed
Risk
33
Moderate Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Day range
Current $487.72
52-week range
Current $487.72
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 958.4M USD | 180.13M USD | — | — | — |
| Cost of goods sold | 56.15M USD | 6.23M USD | — | — | — |
| Gross profit | 902.26M USD | 173.9M USD | — | — | — |
| Research and development | 388.53M USD | 236.72M USD | 272.35M USD | 245.44M USD | 205.16M USD |
| Selling, general, and administrative | 813.83M USD | 435.06M USD | 108.15M USD | 48.13M USD | 37.32M USD |
| Operating expenses | 1.2B USD | 671.78M USD | 380.5M USD | 293.57M USD | 242.48M USD |
| Interest income | 37.36M USD | 46.65M USD | 19.58M USD | 2.19M USD | 363K USD |
| Interest expense | 22.31M USD | 14.67M USD | 12.71M USD | 3.96M USD | — |
| Depreciation and amortization | 1.51M USD | 1.1M USD | 527K USD | 467K USD | 405K USD |
| Operating income | −300.1M USD | −497.88M USD | −380.5M USD | −293.57M USD | −242.48M USD |
| Net income | −288.28M USD | −465.89M USD | −373.63M USD | −295.35M USD | −241.85M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI316.56M0.01%2.3T USD0.03%$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB229.21M0.12%185.3B USD0.03%$286.98-1.41%
State Street SPDR S&P Biotech ETFXBI140.55M1.36%10.08B USD0.35%$150.23-0.44%
Vanguard Morningstar Small-Cap Growth ETFVBK131.54M0.29%44.7B USD0.05%$342.24-1.50%
Vanguard Extended Market ETFVXF118.64M0.12%95.4B USD0.05%$233.49-1.56%
First Trust NYSE Arca Biotechnology Index FundFBT83.75M2.90%2.89B USD0.55%$263.49-0.56%
iShares Biotechnology ETFIBB80.82M0.78%10.4B USD0.44%$203.34+0.12%
Schwab U.S. Small-Cap ETFSCHA51.32M0.24%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
